{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:18:52Z","timestamp":1784661532397,"version":"3.55.0"},"reference-count":249,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T00:00:00Z","timestamp":1561680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL92750"],"award-info":[{"award-number":["HL92750"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS089707"],"award-info":[{"award-number":["NS089707"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL115036"],"award-info":[{"award-number":["HL115036"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Regardless of the cause, symptomatic heart failure (HF) with reduced ejection fraction (rEF) is characterized by pathological activation of the renin\u2013angiotensin\u2013aldosterone system (RAAS) with sodium retention and extracellular fluid expansion (edema). Here, we review the role of active renin, a crucial, upstream enzymatic regulator of the RAAS, as a prognostic and diagnostic plasma biomarker of heart failure with reduced ejection fraction (HFrEF) progression; we also discuss its potential as a pharmacological bio-target in HF therapy. Clinical and experimental studies indicate that plasma renin activity is elevated with symptomatic HFrEF with edema in patients, as well as in companion animals and experimental models of HF. Plasma renin activity levels are also reported to be elevated in patients and animals with rEF before the development of symptomatic HF. Modulation of renin activity in experimental HF significantly reduces edema formation and the progression of systolic dysfunction and improves survival. Thus, specific assessment and targeting of elevated renin activity may enhance diagnostic and therapeutic precision to improve outcomes in appropriate patients with HFrEF.<\/jats:p>","DOI":"10.3390\/ijms20133182","type":"journal-article","created":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T11:20:26Z","timestamp":1561720826000},"page":"3182","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Renin Activity in Heart Failure with Reduced Systolic Function\u2014New Insights"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7633-2210","authenticated-orcid":false,"given":"Ryan D.","family":"Sullivan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Arizona College of Medicine\u2014Phoenix, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika M.","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Arizona College of Medicine\u2014Phoenix, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Arizona College of Medicine\u2014Phoenix, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy L.","family":"Reed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Arizona College of Medicine\u2014Phoenix, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-9029","authenticated-orcid":false,"given":"Inna P.","family":"Gladysheva","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Arizona College of Medicine\u2014Phoenix, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1016\/j.jacc.2016.03.590","article-title":"The Diagnosis and Evaluation of Dilated Cardiomyopathy","volume":"67","author":"Japp","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/CIRCRESAHA.116.309396","article-title":"Dilated Cardiomyopathy: Genetic Determinants and Mechanisms","volume":"121","author":"McNally","year":"2017","journal-title":"Circ. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0140-6736(16)31713-5","article-title":"Dilated cardiomyopathy","volume":"390","author":"Weintraub","year":"2017","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1161\/CIR.0000000000000455","article-title":"Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement from the American Heart Association","volume":"134","author":"Bozkurt","year":"2016","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/clc.22917","article-title":"Sex differences in heart failure","volume":"41","author":"Eisenberg","year":"2018","journal-title":"Clin. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1056\/NEJMcp052699","article-title":"Clinical practice. Acute pulmonary edema","volume":"353","author":"Ware","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/01.CIR.63.3.645","article-title":"Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure","volume":"63","author":"Dzau","year":"1981","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/0002-9149(82)90243-0","article-title":"Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure","volume":"49","author":"Levine","year":"1982","journal-title":"Am. J. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM199908193410806","article-title":"Hormones and hemodynamics in heart failure","volume":"341","author":"Schrier","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1042\/CS20130294","article-title":"The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure","volume":"126","author":"Zucker","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","article-title":"The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications","volume":"54","author":"Triposkiadis","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/01.CIR.74.5.1075","article-title":"Rapid ventricular pacing in the dog: Pathophysiologic studies of heart failure","volume":"74","author":"Armstrong","year":"1986","journal-title":"Circulation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0008-6363(01)00297-8","article-title":"Water and sodium regulation in chronic heart failure: The role of natriuretic peptides and vasopressin","volume":"51","author":"Kalra","year":"2001","journal-title":"Cardiovasc. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1161\/HYPERTENSIONAHA.112.193631","article-title":"Corin overexpression improves cardiac function, heart failure, and survival in mice with dilated cardiomyopathy","volume":"61","author":"Gladysheva","year":"2013","journal-title":"Hypertension"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11906-013-0415-7","article-title":"Corin in natriuretic peptide processing and hypertension","volume":"16","author":"Zhou","year":"2014","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jacc.2014.11.048","article-title":"Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients","volume":"65","author":"Barallat","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1161\/CIRCHEARTFAILURE.114.001174","article-title":"Pro-B-type natriuretic peptide-1-108 processing and degradation in human heart failure","volume":"8","author":"Huntley","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.2935937","article-title":"Atrial natriuretic peptide elevation in congestive heart failure in the human","volume":"231","author":"Burnett","year":"1986","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCHEARTFAILURE.109.895581","article-title":"Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide","volume":"4","author":"Ibebuogu","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.111.960948","article-title":"Process matters: Emerging concepts underlying impaired natriuretic peptide system function in heart failure","volume":"4","author":"Dries","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1155\/2018\/7279036","article-title":"Possible Enzymatic Downregulation of the Natriuretic Peptide System in Patients with Reduced Systolic Function and Heart Failure: A Pilot Study","volume":"2018","author":"Zaidi","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11883-014-0403-7","article-title":"Modulation of the renin-angiotensin-aldosterone system in heart failure","volume":"16","author":"George","year":"2014","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1084\/jem.106.3.439","article-title":"The preparation, purification, and amino acid sequence of a polypeptide renin substrate","volume":"106","author":"Skeggs","year":"1957","journal-title":"J. Exp. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"Group","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"Investigators","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial--the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Survival Study, I. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/postgradmedj-2016-134045","article-title":"The renin-angiotensin-aldosterone system in heart failure for the non-specialist: The past, the present and the future","volume":"93","author":"Orsborne","year":"2017","journal-title":"Postgrad. Med. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: The ASTRONAUT randomized trial","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"JAMA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"88189","DOI":"10.18632\/oncotarget.21112","article-title":"Aliskiren for heart failure: A systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0008-6363(99)00145-5","article-title":"The renin-angiotensin system and experimental heart failure","volume":"43","author":"Wollert","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/cphy.c130040","article-title":"Classical Renin-Angiotensin system in kidney physiology","volume":"4","author":"Sparks","year":"2014","journal-title":"Compr. Physiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/CIRCHEARTFAILURE.112.000289","article-title":"Renin-angiotensin blockade combined with natriuretic peptide system augmentation: Novel therapeutic concepts to combat heart failure","volume":"6","author":"Sangaralingham","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1748-1716.1898.tb00272.x","article-title":"Niere und Kreislauf","volume":"8","author":"Tigerstedt","year":"1898","journal-title":"Skand. Arch. Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1126\/science.2493678","article-title":"Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution","volume":"243","author":"Sielecki","year":"1989","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2215\/CJN.01201005","article-title":"Direct renin inhibition with aliskiren in hypertension and target organ damage","volume":"1","author":"Muller","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/cvr\/5.1.86","article-title":"Kinetics of the human renin and human substrate reaction","volume":"5","author":"Gould","year":"1971","journal-title":"Cardiovasc. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/hrt.76.3_Suppl_3.7","article-title":"The renin-angiotensin system and the heart: A historical review","volume":"76","author":"Cleland","year":"1996","journal-title":"Heart"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/01.HYP.30.3.535","article-title":"Counterregulatory actions of angiotensin-(1-7)","volume":"30","author":"Ferrario","year":"1997","journal-title":"Hypertension"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-0115(00)00138-5","article-title":"Angiotensin-(1-7): An update","volume":"91","author":"Santos","year":"2000","journal-title":"Regul. Pept."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"H1560","DOI":"10.1152\/ajpheart.00941.2004","article-title":"Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor","volume":"289","author":"Tallant","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","article-title":"Renin-angiotensin system revisited","volume":"264","author":"Fyhrquist","year":"2008","journal-title":"J. Intern. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.phrs.2012.04.001","article-title":"Modeling of angiotensin II-angiotensin-(1-7) counterbalance in disease progression in spontaneously hypertensive rats treated with\/without perindopril","volume":"66","author":"Zhou","year":"2012","journal-title":"Pharm. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-12-0341","article-title":"Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: New players of the renin-angiotensin system","volume":"216","author":"Santos","year":"2013","journal-title":"J. Endocrinol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/HYPERTENSIONAHA.111.173344","article-title":"Angiotensin (1-7) induces MAS receptor internalization","volume":"58","author":"Gironacci","year":"2011","journal-title":"Hypertension"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00041552-200501000-00011","article-title":"Update on the role of the AT2 receptor","volume":"14","author":"Carey","year":"2005","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ajh\/hpw121","article-title":"AT2 Receptors: Potential Therapeutic Targets for Hypertension","volume":"30","author":"Carey","year":"2017","journal-title":"Am. J. Hypertens."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/01.HYP.0000128531.39964.c0","article-title":"Cardiac angiotensin AT2 receptor: What exactly does it do?","volume":"43","author":"Booz","year":"2004","journal-title":"Hypertension"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.pharmthera.2008.08.009","article-title":"AT2 receptors: Functional relevance in cardiovascular disease","volume":"120","author":"Jones","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"132","DOI":"10.18773\/austprescr.2009.064","article-title":"Renin inhibitors\u2014Mechanisms of action","volume":"32","author":"Campbell","year":"2009","journal-title":"Aust. Prescr."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1161\/hh0701.089175","article-title":"Enhanced angiotensin II activity in heart failure: Reevaluation of the counterregulatory hypothesis of receptor subtypes","volume":"88","author":"Opie","year":"2001","journal-title":"Circ. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.0000096609.73772.C5","article-title":"Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system","volume":"109","author":"Levy","year":"2004","journal-title":"Circulation"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1470320309347785","article-title":"The angiotensin II type 2 receptor in cardiovascular disease","volume":"11","author":"Lemarie","year":"2010","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"141039","DOI":"10.1155\/2011\/141039","article-title":"Genetically modified mouse models used for studying the role of the AT2 receptor in cardiac hypertrophy and heart failure","volume":"2011","author":"Avila","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1073\/pnas.81.16.5026","article-title":"Human renin gene: Structure and sequence analysis","volume":"81","author":"Hobart","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/pro.5560070401","article-title":"Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes","volume":"7","author":"Khan","year":"1998","journal-title":"Protein Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/01.HYP.0000135678.20725.54","article-title":"Enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats","volume":"44","author":"Kobori","year":"2004","journal-title":"Hypertension"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00424-012-1105-z","article-title":"The (pro)renin receptor. A decade of research: What have we learned?","volume":"465","author":"Krop","year":"2013","journal-title":"Pflug. Arch."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1152\/physrev.00011.2009","article-title":"Physiology of kidney renin","volume":"90","author":"Castrop","year":"2010","journal-title":"Physiol. Rev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/ajh.2011.246","article-title":"Control of renin synthesis and secretion","volume":"25","author":"Kurtz","year":"2012","journal-title":"Am. J. Hypertens."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"260298","DOI":"10.1155\/2013\/260298","article-title":"Renin and the IGFII\/M6P receptor system in cardiac biology","volume":"2013","author":"Heger","year":"2013","journal-title":"Sci. World J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/01.RES.0000251057.35537.d3","article-title":"The calcium paradoxon of renin release: Calcium suppresses renin exocytosis by inhibition of calcium-dependent adenylate cyclases AC5 and AC6","volume":"99","author":"Grunberger","year":"2006","journal-title":"Circ. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00143.2009","article-title":"The role of calcium in the regulation of renin secretion","volume":"298","author":"Beierwaltes","year":"2010","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1073\/pnas.83.13.4769","article-title":"Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process","volume":"83","author":"Kurtz","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9003","DOI":"10.1073\/pnas.95.15.9003","article-title":"Endogenous or overexpressed cGMP-dependent protein kinases inhibit cAMP-dependent renin release from rat isolated perfused kidney, microdissected glomeruli, and isolated juxtaglomerular cells","volume":"95","author":"Gambaryan","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1172\/JCI4044","article-title":"Role of cGMP-kinase II in the control of renin secretion and renin expression","volume":"102","author":"Wagner","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00109-012-0894-z","article-title":"Emergence and evolution of the renin-angiotensin-aldosterone system","volume":"90","author":"Fournier","year":"2012","journal-title":"J. Mol. Med. (Berl.)"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/hrt.2006.107706","article-title":"Renin: Friend or foe?","volume":"93","author":"Brown","year":"2007","journal-title":"Heart"},{"key":"ref_83","first-page":"F486","article-title":"Renin release from isolated juxtaglomerular apparatus depends on macula densa chloride transport","volume":"260","author":"Lorenz","year":"1991","journal-title":"Am. J. Physiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/ki.1992.39","article-title":"Pressure dependent modulation of renin release in isolated perfused glomeruli","volume":"41","author":"Bock","year":"1992","journal-title":"Kidney Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1172\/JCI119680","article-title":"Biomechanical coupling in renin-releasing cells","volume":"100","author":"Carey","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(78)91298-9","article-title":"Factor XII in endogenous activation of inactive renin","volume":"1","author":"Tatemichi","year":"1978","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1073\/pnas.76.11.5914","article-title":"Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein","volume":"76","author":"Sealey","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/283482a0","article-title":"Evidence for a role of plasma kallikrein in the activation of prorenin","volume":"283","author":"Rumpf","year":"1980","journal-title":"Nature"},{"key":"ref_89","first-page":"2425","article-title":"Effect of Captoril on Inactive Renin and Contact Phase of Coagulation System","volume":"4","author":"Mantero","year":"1982","journal-title":"Clin. Exp. Hypertens."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/oxfordjournals.eurheartj.a061706","article-title":"The contact phase of blood coagulation and renin activation in essential hypertension before and after captopril","volume":"5","author":"Patrassi","year":"1984","journal-title":"Eur. Heart J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/ki.1994.435","article-title":"Proteolytic processing of human prorenin in renal and non-renal tissues","volume":"46","author":"Reudelhuber","year":"1994","journal-title":"Kidney Int."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0021-9258(18)61528-5","article-title":"Two-step prorenin-renin conversion. Isolation of an intermediary form of activated prorenin","volume":"262","author":"Derkx","year":"1987","journal-title":"J. Biol. Chem."},{"key":"ref_93","first-page":"2133","article-title":"The reversible activation of inactive renin in human plasma: Role of acid and of plasma kallikrein and plasmin","volume":"4","author":"Leckie","year":"1982","journal-title":"Clin. Exp. Hypertens. A"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"R1212","DOI":"10.1152\/ajpregu.00830.2009","article-title":"Cathepsin B is not the processing enzyme for mouse prorenin","volume":"298","author":"Mercure","year":"2010","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI0214276","article-title":"Pivotal role of the renin\/prorenin receptor in angiotensin II production and cellular responses to renin","volume":"109","author":"Nguyen","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.1073\/pnas.84.22.7837","article-title":"Human renin biosynthesis and secretion in normal and ischemic kidneys","volume":"84","author":"Pratt","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1470320308097674","article-title":"Prorenin and the (pro)renin receptor: Binding kinetics, signalling and interaction with aliskiren","volume":"9","author":"Batenburg","year":"2008","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11906-010-0172-9","article-title":"Renin and prorenin receptor in hypertension: what\u2019s new?","volume":"13","author":"Nguyen","year":"2011","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10741-011-9262-2","article-title":"New roles for renin and prorenin in heart failure and cardiorenal crosstalk","volume":"17","author":"Schroten","year":"2012","journal-title":"Heart Fail. Rev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2013.00155","article-title":"Autophagy and the (Pro)renin Receptor","volume":"4","author":"Binger","year":"2013","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.HYP.24.1.37","article-title":"Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis","volume":"24","author":"Danser","year":"1994","journal-title":"Hypertension"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/en.2003-0150","article-title":"Minireview: Overview of the renin-angiotensin system--an endocrine and paracrine system","volume":"144","author":"Lavoie","year":"2003","journal-title":"Endocrinology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3317\/jraas.2005.025","article-title":"Renin, prorenin and the putative (pro)renin receptor","volume":"6","author":"Danser","year":"2005","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of local renin-angiotensin systems","volume":"86","author":"Paul","year":"2006","journal-title":"Physiol. Rev."},{"key":"ref_105","first-page":"483","article-title":"Binding properties of rat prorenin and renin to the recombinant rat renin\/prorenin receptor prepared by a baculovirus expression system","volume":"18","author":"Nabi","year":"2006","journal-title":"Int J. Mol. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/01.CIR.86.1.138","article-title":"Expression of the angiotensinogen gene and localization of its protein in the human heart","volume":"86","author":"Sawa","year":"1992","journal-title":"Circulation"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.92.9.2690","article-title":"Cardiac renin-angiotensin system in the hypertrophied heart","volume":"92","author":"Iwai","year":"1995","journal-title":"Circulation"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0002-9149(87)90795-8","article-title":"Decreased heart rate variability and its association with increased mortality after acute myocardial infarction","volume":"59","author":"Kleiger","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1161\/01.HYP.30.6.1389","article-title":"Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells","volume":"30","author":"Danser","year":"1997","journal-title":"Hypertension"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1172\/JCI21398","article-title":"Inhibition of diabetic nephropathy by a decoy peptide corresponding to the \"handle\" region for nonproteolytic activation of prorenin","volume":"114","author":"Ichihara","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/01.HYP.0000215838.48170.0b","article-title":"Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension","volume":"47","author":"Ichihara","year":"2006","journal-title":"Hypertension"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/01.HYP.0000215952.91959.4a","article-title":"Prorenin: Back into the arena","volume":"47","author":"Danser","year":"2006","journal-title":"Hypertension"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.ki.5000079","article-title":"Receptor-mediated actions of renin and prorenin","volume":"69","author":"Oliver","year":"2006","journal-title":"Kidney Int."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.ki.5000265","article-title":"Renin\/prorenin receptors","volume":"69","author":"Nguyen","year":"2006","journal-title":"Kidney Int."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1517\/13543784.15.10.1131","article-title":"The (pro)renin receptor: Therapeutic consequences","volume":"15","author":"Nguyen","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1681\/ASN.2006010029","article-title":"Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice","volume":"17","author":"Ichihara","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.ki.5000011","article-title":"Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms","volume":"69","author":"Huang","year":"2006","journal-title":"Kidney Int."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1161\/HYPERTENSIONAHA.108.127258","article-title":"Soluble form of the (pro)renin receptor generated by intracellular cleavage by furin is secreted in plasma","volume":"53","author":"Cousin","year":"2009","journal-title":"Hypertension"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/hr.2010.284","article-title":"The (pro)renin receptor is cleaved by ADAM19 in the Golgi leading to its secretion into extracellular space","volume":"34","author":"Yoshikawa","year":"2011","journal-title":"Hypertens. Res."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Ohashi, N., Isobe, S., Ishigaki, S., Suzuki, T., Iwakura, T., Ono, M., Fujikura, T., Tsuji, T., Otsuka, A., and Ishii, Y. (2016). Plasma Soluble (Pro)renin Receptor Reflects Renal Damage. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156165"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.peptides.2018.04.010","article-title":"Elevated plasma soluble (pro)renin receptor levels are associated with left ventricular remodeling and renal function in chronic heart failure patients with reduced ejection fraction","volume":"111","author":"Gong","year":"2019","journal-title":"Peptides"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/hr.2009.186","article-title":"The increase in renin during renin inhibition: Does it result in harmful effects by the (pro)renin receptor?","volume":"33","author":"Danser","year":"2010","journal-title":"Hypertens. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1681\/ASN.2015080915","article-title":"Renal Atp6ap2\/(Pro)renin Receptor Is Required for Normal Vacuolar H+-ATPase Function but Not for the Renin-Angiotensin System","volume":"27","author":"Trepiccione","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.ATV.21.6.911","article-title":"Prorenin accumulation and activation in human endothelial cells: Importance of mannose 6-phosphate receptors","volume":"21","author":"Saris","year":"2001","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00109-008-0319-1","article-title":"The (pro)renin receptors","volume":"86","author":"Nguyen","year":"2008","journal-title":"J. Mol. Med. (Berl.)"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"H1706","DOI":"10.1152\/ajpheart.2001.280.4.H1706","article-title":"High-affinity prorenin binding to cardiac man-6-P\/IGF-II receptors precedes proteolytic activation to renin","volume":"280","author":"Saris","year":"2001","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1042\/CS20120042","article-title":"(Pro)renin and its receptors: Pathophysiological implications","volume":"123","author":"Batenburg","year":"2012","journal-title":"Clin. Sci. (Lond.)"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"E306","DOI":"10.1152\/ajpendo.00127.2005","article-title":"Roles of insulin-like growth factor II in cardiomyoblast apoptosis and in hypertensive rat heart with abdominal aorta ligation","volume":"291","author":"Lee","year":"2006","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/cdd.2014.46","article-title":"ANG II promotes IGF-IIR expression and cardiomyocyte apoptosis by inhibiting HSF1 via JNK activation and SIRT1 degradation","volume":"21","author":"Huang","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijcard.2017.10.102","article-title":"Inhibition of HSF2 SUMOylation via MEL18 upregulates IGF-IIR and leads to hypertension-induced cardiac hypertrophy","volume":"257","author":"Huang","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/jcp.25945","article-title":"HSF1 phosphorylation by ERK\/GSK3 suppresses RNF126 to sustain IGF-IIR expression for hypertension-induced cardiomyocyte hypertrophy","volume":"233","author":"Huang","year":"2018","journal-title":"J. Cell Physiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1582-4934.2011.01414.x","article-title":"Elevation of IGF-2 receptor and the possible underlying implications in end-stage heart failure patients before and after heart transplantation","volume":"16","author":"Wei","year":"2012","journal-title":"J. Cell Mol. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cvr\/cvq313","article-title":"Controlling cardiomyocyte length: The role of renin and PPAR-{gamma}","volume":"89","author":"Hinrichs","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"26150","DOI":"10.1074\/jbc.M703276200","article-title":"The insulin-like growth factor type 1 and insulin-like growth factor type 2\/mannose-6-phosphate receptors independently regulate ERK1\/2 activity in HEK293 cells","volume":"282","author":"Lee","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1161\/HYPERTENSIONAHA.107.092817","article-title":"Peroxisome proliferator-activated receptor-gamma is involved in the control of renin gene expression","volume":"50","author":"Todorov","year":"2007","journal-title":"Hypertension"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0002-9440(10)63823-0","article-title":"Tissue-specific inactivation of murine M6P\/IGF2R","volume":"162","author":"Wylie","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00109-008-0330-6","article-title":"Aliskiren--mode of action and preclinical data","volume":"86","author":"Muller","year":"2008","journal-title":"J. Mol. Med. (Berl.)"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0167-5273(00)00172-8","article-title":"Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones","volume":"73","author":"Teisman","year":"2000","journal-title":"Int. J. Cardiol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"16810","DOI":"10.1073\/pnas.0611202104","article-title":"Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals","volume":"104","author":"Bodyak","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ahj.2013.05.009","article-title":"Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: An open-label, blinded end point, randomized prospective trial (VitD-CHF trial)","volume":"166","author":"Schroten","year":"2013","journal-title":"Am. Heart J."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0167-5273(94)90127-9","article-title":"Plasma renin activity in chagasic patients with and without congestive heart failure","volume":"47","author":"Bellabarba","year":"1994","journal-title":"Int. J. Cardiol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0034-5288(95)90055-1","article-title":"Activation of the renin-angiotensin system in dogs with asymptomatic and symptomatic dilated cardiomyopathy","volume":"59","author":"Koch","year":"1995","journal-title":"Res. Vet. Sci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ehj.2003.10.030","article-title":"The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT","volume":"25","author":"Latini","year":"2004","journal-title":"Eur. Heart J."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jchf.2014.09.003","article-title":"Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure","volume":"3","author":"Mentz","year":"2015","journal-title":"JACC Heart Fail."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Tripathi, R., Sullivan, R., Fan, T.M., Wang, D., Sun, Y., Reed, G.L., and Gladysheva, I.P. (2017). Enhanced heart failure, mortality and renin activation in female mice with experimental dilated cardiomyopathy. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0189315"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/BF00637388","article-title":"Circadian variations in plasma renin activity, catecholamines and aldosterone during exercise in women","volume":"58","author":"Stephenson","year":"1989","journal-title":"Eur. J. Appl. Physiol. Occup. Physiol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/clinchem\/37.10.1811","article-title":"Plasma renin activity and plasma prorenin assays","volume":"37","author":"Sealey","year":"1991","journal-title":"Clin. Chem."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"11753","DOI":"10.1016\/S0021-9258(19)49762-7","article-title":"Reversible cryoactivation of recombinant human prorenin","volume":"267","author":"Pitarresi","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1161\/HYPERTENSIONAHA.108.110924","article-title":"Critical review of prorenin and (pro)renin receptor research","volume":"51","author":"Campbell","year":"2008","journal-title":"Hypertension"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1258\/0004563001899401","article-title":"Aldosterone and renin measurements","volume":"37","author":"Cartledge","year":"2000","journal-title":"Ann. Clin. Biochem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1373\/clinchem.2008.118000","article-title":"Activity assays and immunoassays for plasma Renin and prorenin: Information provided and precautions necessary for accurate measurement","volume":"55","author":"Campbell","year":"2009","journal-title":"Clin. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1373\/clinchem.2004.033654","article-title":"Direct renin assay and plasma renin activity assay compared","volume":"50","author":"Hartman","year":"2004","journal-title":"Clin. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1253\/circj.71.915","article-title":"Comparison of active renin concentration and plasma renin activity as a prognostic predictor in patients with heart failure","volume":"71","author":"Tsutamoto","year":"2007","journal-title":"Circ. J."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1258\/acb.2010.010171","article-title":"The clinical utility of two renin mass methods to detect primary hyperaldosteronism compared with renin activity","volume":"48","author":"Wedatilake","year":"2011","journal-title":"Ann. Clin. Biochem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/HYPERTENSIONAHA.117.09078","article-title":"Rapid Screening of Primary Aldosteronism by a Novel Chemiluminescent Immunoassay","volume":"70","author":"Morimoto","year":"2017","journal-title":"Hypertension"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1373\/clinchem.2017.278705","article-title":"Low- and High-renin Heart Failure Phenotypes with Clinical Implications","volume":"64","author":"Pavo","year":"2018","journal-title":"Clin. Chem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1006\/abio.1993.1207","article-title":"A continuous fluorescence assay of renin activity","volume":"210","author":"Wang","year":"1993","journal-title":"Anal. Biochem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1042\/BJ20040729","article-title":"Highly sensitive intramolecularly quenched fluorogenic substrates for renin based on the combination of L-2-amino-3-(7-methoxy-4-coumaryl)propionic acid with 2,4-dinitrophenyl groups at various positions","volume":"382","author":"Paschalidou","year":"2004","journal-title":"Biochem. J."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2460\/ajvr.70.11.1315","article-title":"Measurement of plasma renin concentration in cats by use of a fluorescence resonance energy transfer peptide substrate of renin","volume":"70","author":"Schmiedt","year":"2009","journal-title":"Am. J. Vet. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.rvsc.2011.12.004","article-title":"Bilateral renal ischemia as a model of acute kidney injury in cats","volume":"93","author":"Schmiedt","year":"2012","journal-title":"Res. Vet. Sci."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nm.2603","article-title":"Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension","volume":"18","author":"Prysyazhna","year":"2012","journal-title":"Nat. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1073\/pnas.1302641110","article-title":"Primary aldosteronism and impaired natriuresis in mice underexpressing TGFbeta1","volume":"110","author":"Kakoki","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1152\/japplphysiol.00053.2012","article-title":"Angiotensin II receptor blocker improves the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice","volume":"114","author":"Takada","year":"2013","journal-title":"J. Appl. Physiol. (1985)"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1161\/HYPERTENSIONAHA.113.02164","article-title":"Atrial natriuretic peptide affects cardiac remodeling, function, heart failure, and survival in a mouse model of dilated cardiomyopathy","volume":"63","author":"Wang","year":"2014","journal-title":"Hypertension"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Sullivan, R.D., Mehta, R.M., Tripathi, R., Gladysheva, I.P., and Reed, G.L. (2018). Abstract 16743: Targeting renin activity in heart failure: precision therapy with aliskiren improves systolic function and prolongs survival in female experimental dilated cardiomyopathy. Circulation, 138.","DOI":"10.1161\/circ.138.suppl_1.16743"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.amjcard.2011.03.034","article-title":"Prognostic value of plasma renin activity in heart failure","volume":"108","author":"Vergaro","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ijcard.2012.03.061","article-title":"Prognostic value of plasma renin activity in heart failure patients with chronic kidney disease","volume":"167","author":"Poletti","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/jch.12419","article-title":"Plasma renin activity and its association with ischemic heart disease, congestive heart failure, and cerebrovascular disease in a large hypertensive cohort","volume":"16","author":"Sim","year":"2014","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.krcp.2016.07.004","article-title":"Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressure","volume":"35","author":"Bhandari","year":"2016","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1470320317729919","DOI":"10.1177\/1470320317729919","article-title":"Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy","volume":"18","author":"Nijst","year":"2017","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/0002-8703(90)90125-H","article-title":"ACE inhibition improves vagal reactivity in patients with heart failure","volume":"120","author":"Osterziel","year":"1990","journal-title":"Am. Heart J."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/tvjl.2001.0616","article-title":"Canine idiopathic dilated cardiomyopathy. Part II: Pathophysiology and therapy","volume":"162","author":"Borgarelli","year":"2001","journal-title":"Vet. J."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1939-1676.1995.tb03266.x","article-title":"Idiopathic dilated cardiomyopathy in dogs: Survival and prognostic indicators","volume":"9","author":"Monnet","year":"1995","journal-title":"J. Vet. Intern. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1053\/tvjl.2001.0571","article-title":"Canine idiopathic dilated cardiomyopathy. Part I: Aetiology, clinical characteristics, epidemiology and pathology","volume":"162","author":"Tidholm","year":"2001","journal-title":"Vet. J."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jvc.2006.01.003","article-title":"Survival in dogs with dilated cardiomyopathy and congestive heart failure treated with digoxin, furosemide and propranolol: A retrospective study of 62 dogs","volume":"8","author":"Tidholm","year":"2006","journal-title":"J. Vet. Cardiol."},{"key":"ref_176","unstructured":"Ettinger, S.J. (1995). Myocardial Diseases. Textbook of Veterinary Internal Medicine, W. B. Saunders. [4th ed.]."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5326\/15473317-33-6-544","article-title":"A retrospective study of canine dilated cardiomyopathy (189 cases)","volume":"33","author":"Tidholm","year":"1997","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5326\/15473317-36-2-125","article-title":"The prevalence of cardiomyopathy in the Irish wolfhound: A clinical study of 500 dogs","volume":"36","author":"Vollmar","year":"2000","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2460\/ajvr.2001.62.961","article-title":"Effects of dilated cardiomyopathy on the renin-angiotensin-aldosterone system, atrial natriuretic peptide activity, and thyroid hormone concentrations in dogs","volume":"62","author":"Tidholm","year":"2001","journal-title":"Am. J. Vet. Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1034\/j.1600-0684.2000.290106.x","article-title":"Dilative cardiomyopathy leading to congestive heart failure in a male squirrel monkey (Saimiri sciureus)","volume":"29","author":"Tolwani","year":"2000","journal-title":"J. Med. Primatol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/01.CIR.101.2.185","article-title":"Dilated cardiomyopathy associated with simian AIDS in nonhuman primates","volume":"101","author":"Shannon","year":"2000","journal-title":"Circulation"},{"key":"ref_182","first-page":"80","article-title":"Successful treatment of idiopathic dilated cardiomyopathy in an adult chimpanzee (Pan troglodytes)","volume":"55","author":"Sleeper","year":"2005","journal-title":"Comp. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1600-0684.2010.00403.x","article-title":"The normal and abnormal owl monkey (Aotus sp.) heart: Looking at cardiomyopathy changes with echocardiography and electrocardiography","volume":"39","author":"Rajendra","year":"2010","journal-title":"J. Med. Primatol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jmp.12108","article-title":"Dilated cardiomyopathy in a De Brazza\u2019s monkey (Cercopithecus neglectus)","volume":"43","author":"Felkai","year":"2014","journal-title":"J. Med. Primatol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/RES.0b013e3182582523","article-title":"Animal models of heart failure: A scientific statement from the American Heart Association","volume":"111","author":"Houser","year":"2012","journal-title":"Circ. Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2538263","DOI":"10.1155\/2016\/2538263","article-title":"Experimental Heart Failure Models and Their Pathophysiological Characterization","volume":"2016","author":"Becher","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1161\/01.HYP.0000149717.55920.45","article-title":"Transcriptional regulation of renin: An update","volume":"45","author":"Pan","year":"2005","journal-title":"Hypertension"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1161\/01.HYP.18.4.446","article-title":"Structure, expression, and regulation of the murine renin genes","volume":"18","author":"Sigmund","year":"1991","journal-title":"Hypertension"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/j.1460-2075.1984.tb01846.x","article-title":"Evolution of aspartyl proteases by gene duplication: The mouse renin gene is organized in two homologous clusters of four exons","volume":"3","author":"Holm","year":"1984","journal-title":"EMBO J."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-201X.2004.01315.x","article-title":"Plasma renin in mice with one or two renin genes","volume":"181","author":"Hansen","year":"2004","journal-title":"Acta Physiol. Scand."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/HYPERTENSIONAHA.110.163840","article-title":"Creation and characterization of a renin knockout rat","volume":"57","author":"Moreno","year":"2011","journal-title":"Hypertension"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"18185","DOI":"10.1074\/jbc.272.29.18185","article-title":"Renin-1 is essential for normal renal juxtaglomerular cell granulation and macula densa morphology","volume":"272","author":"Clark","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1161\/01.HYP.28.6.1126","article-title":"Targeted inactivation of the Ren-2 gene in mice","volume":"28","author":"Sharp","year":"1996","journal-title":"Hypertension"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.1073\/pnas.89.16.7806","article-title":"Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes","volume":"89","author":"Ganten","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"11617","DOI":"10.1016\/S0021-9258(19)50246-0","article-title":"Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes","volume":"268","author":"Fukamizu","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1172\/JCI118497","article-title":"Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes","volume":"97","author":"Merrill","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1538\/expanim.46.171","article-title":"Development of genetically engineered mice with hypertension and hypotension","volume":"46","author":"Sugiyama","year":"1997","journal-title":"Exp. Anim."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-201X.2004.01332.x","article-title":"Transgenic mice for studies of the renin-angiotensin system in hypertension","volume":"181","author":"Lavoie","year":"2004","journal-title":"Acta Physiol. Scand."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/01.HYP.0000227932.13687.60","article-title":"Genetic basis of hypertension: Revisiting angiotensinogen","volume":"48","author":"Dickson","year":"2006","journal-title":"Hypertension"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1161\/01.CIR.96.7.2385","article-title":"Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems","volume":"96","author":"Spinale","year":"1997","journal-title":"Circulation"},{"key":"ref_201","first-page":"H1625","article-title":"Hemodynamic and hormonal effects of renin inhibition in ovine heart failure","volume":"258","author":"Fitzpatrick","year":"1990","journal-title":"Am. J. Physiol."},{"key":"ref_202","first-page":"H2281","article-title":"Possible regulation of renin release by ANP in dogs with heart failure","volume":"268","author":"Kanamori","year":"1995","journal-title":"Am. J. Physiol."},{"key":"ref_203","first-page":"H228","article-title":"Plasma renin activity in heart failure-prone SHHF\/Mcc-facp rats","volume":"273","author":"Holycross","year":"1997","journal-title":"Am. J. Physiol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/cvr\/cvv248","article-title":"The renin-angiotensin system promotes arrhythmogenic substrates and lethal arrhythmias in mice with non-ischaemic cardiomyopathy","volume":"109","author":"Yamada","year":"2016","journal-title":"Cardiovasc. Res."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1172\/JCI1362","article-title":"Regulation of Ca2+ signaling in transgenic mouse cardiac myocytes overexpressing calsequestrin","volume":"101","author":"Jones","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"22251","DOI":"10.1074\/jbc.274.32.22251","article-title":"Defective beta-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression","volume":"274","author":"Cho","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Hara, T., Nishimura, S., Yamamoto, T., Kajimoto, Y., Kusumoto, K., Kanagawa, R., Ikeda, S., and Nishimoto, T. (2018). TAK-272 (imarikiren), a novel renin inhibitor, improves cardiac remodeling and mortality in a murine heart failure model. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202176"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1172\/JCI2950","article-title":"Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart","volume":"101","author":"Fentzke","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"H210","DOI":"10.1152\/ajpheart.2000.279.1.H210","article-title":"Effects of exercise training on LV performance and mortality in a murine model of dilated cardiomyopathy","volume":"279","author":"Spencer","year":"2000","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/HYPERTENSIONAHA.115.06300","article-title":"Depressed Corin Levels Indicate Early Systolic Dysfunction Before Increases of Atrial Natriuretic Peptide\/B-Type Natriuretic Peptide and Heart Failure Development","volume":"67","author":"Tripathi","year":"2016","journal-title":"Hypertension"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0008-6363(01)00479-5","article-title":"Renin angiotensin system and gender differences in the cardiovascular system","volume":"53","author":"Fischer","year":"2002","journal-title":"Cardiovasc. Res."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fimmu.2016.00031","article-title":"Early Ovariectomy Results in Reduced Numbers of CD11c+\/CD11b+ Spleen Cells and Impacts Disease Expression in Murine Lupus","volume":"7","author":"Cunningham","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jacc.2007.10.027","article-title":"Renin inhibition in hypertension","volume":"51","author":"Gradman","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1016\/j.bmcl.2010.08.087","article-title":"Piperidine-based renin inhibitors: Upper chain optimization","volume":"20","author":"Corminboeuf","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1021\/acsmedchemlett.6b00251","article-title":"Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor","volume":"7","author":"Imaeda","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/0975-7406.80764","article-title":"Aliskiren: An orally active renin inhibitor","volume":"3","author":"Wal","year":"2011","journal-title":"J. Pharm. Bioallied. Sci."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ejheart.2007.09.002","article-title":"Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure","volume":"9","author":"Seed","year":"2007","journal-title":"Eur. J. Heart Fail."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/eurheartj\/ehq522","article-title":"Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction","volume":"32","author":"Solomon","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ahj.2014.12.016","article-title":"Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with Chronic Heart Failure and Renal Dysfunction)","volume":"169","author":"Schroten","year":"2015","journal-title":"Am. Heart J."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/ejhf.408","article-title":"The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): Revised statistical analysis plan and baseline characteristics","volume":"17","author":"Krum","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/01.HYP.29.2.634","article-title":"Additive effects of losartan and enalapril on blood pressure and plasma active renin","volume":"29","author":"Azizi","year":"1997","journal-title":"Hypertension"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ejhf.973","article-title":"Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: The ASTRONAUT trial","volume":"20","author":"Vaduganathan","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Luo, Y., and Chen, Q. (2018). Efficacy of aliskiren supplementation for heart failure: A meta-analysis of randomized controlled trials. Herz.","DOI":"10.1007\/s00059-018-4679-1"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11906-006-0090-z","article-title":"New drugs for hypertension: What do they offer?","volume":"8","author":"Gradman","year":"2006","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","article-title":"Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension","volume":"49","author":"Oh","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.hjh.0000202812.72341.99","article-title":"Renin inhibition with aliskiren: Where are we now, and where are we going?","volume":"24","author":"Azizi","year":"2006","journal-title":"J. Hypertens."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): Comparison with enalapril","volume":"39","author":"Nussberger","year":"2002","journal-title":"Hypertension"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ. Heart Fail."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/eurjhf\/hfr034","article-title":"Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: The Aliskiren Observation of Heart Failure Treatment study","volume":"13","author":"Pitt","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nrd3431","article-title":"Novel therapeutic targets for the treatment of heart failure","volume":"10","author":"Tamargo","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/01.HYP.24.5.571","article-title":"Chronic administration of aldosterone depresses baroreceptor reflex function in the dog","volume":"24","author":"Wang","year":"1994","journal-title":"Hypertension"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am. J. Cardiol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ahj.2018.03.019","article-title":"The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial","volume":"201","author":"Upadhya","year":"2018","journal-title":"Am. Heart J."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","article-title":"Epidemiology and aetiology of heart failure","volume":"13","author":"Ziaeian","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(17)31071-1","article-title":"Heart failure","volume":"390","author":"Metra","year":"2017","journal-title":"Lancet"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/CRD.0000000000000131","article-title":"Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction: The Misleading Definition of the New Guidelines","volume":"25","author":"Fedele","year":"2017","journal-title":"Cardiol. Rev."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: A position paper from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1755-5922.2011.00292.x","article-title":"Combination angiotensin converting enzyme and direct renin inhibition in heart failure following experimental myocardial infarction","volume":"31","author":"Connelly","year":"2013","journal-title":"Cardiovasc. Ther."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1042\/CS20120448","article-title":"Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: Comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor","volume":"124","author":"Thomas","year":"2013","journal-title":"Clin. Sci. (Lond.)"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1161\/HYPERTENSIONAHA.108.116350","article-title":"Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure","volume":"52","author":"Westermann","year":"2008","journal-title":"Hypertension"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.biopha.2011.11.020","article-title":"Aliskiren attenuates myocardial apoptosis and oxidative stress in chronic murine model of cardiomyopathy","volume":"66","author":"Rashikh","year":"2012","journal-title":"Biomed. Pharm."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/HYPERTENSIONAHA.112.201889","article-title":"Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension","volume":"61","author":"Moniwa","year":"2013","journal-title":"Hypertension"},{"key":"ref_243","first-page":"891","article-title":"[Aliskiren inhibits angiotensin II\/angiotensin 1-7(Ang II\/Ang1-7) signal pathway in rats with diabetic nephropathy]","volume":"34","author":"Ding","year":"2018","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/07853890.2017.1313447","article-title":"Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease","volume":"49","author":"Antlanger","year":"2017","journal-title":"Ann. Med."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1440-1681.2011.05572.x","article-title":"Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart","volume":"38","author":"Campbell","year":"2011","journal-title":"Clin. Exp. Pharm. Physiol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1161\/HYPERTENSIONAHA.113.02902","article-title":"Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism","volume":"63","author":"Koid","year":"2014","journal-title":"Hypertension"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"519130","DOI":"10.1155\/2013\/519130","article-title":"Effect of the Direct Renin Inhibitor Aliskiren on Urinary Albumin Excretion in Spontaneous Type 2 Diabetic KK-A (y) Mouse","volume":"2013","author":"Furukawa","year":"2013","journal-title":"Int. J. Nephrol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00395-010-0120-5","article-title":"The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice","volume":"105","author":"Poss","year":"2010","journal-title":"Basic Res. Cardiol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1042\/CS20130382","article-title":"Aliskiren limits abdominal aortic aneurysm, ventricular hypertrophy and atherosclerosis in an apolipoprotein-E-deficient mouse model","volume":"127","author":"Seto","year":"2014","journal-title":"Clin. Sci. (Lond.)"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/13\/3182\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:02:13Z","timestamp":1760187733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/13\/3182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,28]]},"references-count":249,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2019,7]]}},"alternative-id":["ijms20133182"],"URL":"https:\/\/doi.org\/10.3390\/ijms20133182","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,28]]}}}